Johnson & Johnson (NYSE:JNJ) is Atlas Brown Inc.’s Largest Position
Atlas Brown Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,275 shares of the company’s stock after buying an additional 343 shares during the period. Johnson & Johnson makes up about 3.9% of Atlas Brown Inc.’s portfolio, making the stock its largest position. Atlas Brown Inc.’s holdings in Johnson & Johnson were worth $4,402,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after buying an additional 6 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $117,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth approximately $186,000. Finally, Taylor Wealth Management Partners raised its position in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (JNJ) traded up 0.01% during midday trading on Friday, reaching $133.10. 4,270,571 shares of the company’s stock traded hands. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a 50-day moving average of $133.09 and a 200-day moving average of $126.30. The company has a market capitalization of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter in the previous year, the business posted $1.74 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.
A number of equities analysts have recently commented on the stock. Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 price target on the stock. in a report on Monday, May 8th. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Wells Fargo & Company reissued a “market perform” rating and issued a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, UBS AG reissued a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $133.72.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.